These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31483218)

  • 1. Time of administration of rabies immunoglobulins and adequacy of antibody response upon post-exposure prophylaxis: a descriptive retrospective study in Belgium.
    Soentjens P; Croughs M; Burm C; Declerq S; Clerinx J; Maniewski U; Van Den Broucke S; Theunissen C; Huits R; Brosius I; Florence E; Kenyon C; Van Griensven J; Van Ierssel S; Lynen L; Balliauw K; Van Gucht S; Van Esbroeck M; Vlieghe E; Bottieau E; Van Herrewege Y
    Acta Clin Belg; 2021 Apr; 76(2):91-97. PubMed ID: 31483218
    [No Abstract]   [Full Text] [Related]  

  • 2. Using serology to assist with complicated post-exposure prophylaxis for rabies and Australian bat lyssavirus.
    Conroy N; Vlack S; Williams JM; Patten JJ; Horvath RL; Lambert SB
    PLoS Negl Trop Dis; 2013; 7(2):e2066. PubMed ID: 23469301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies.
    Lang J; Gravenstein S; Briggs D; Miller B; Froeschle J; Dukes C; Le Mener V; Lutsch C
    Biologicals; 1998 Mar; 26(1):7-15. PubMed ID: 9637744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial.
    Pineda-Peña AC; Jiang Q; Petit C; Korejwo-Peyramond J; Donazzolo Y; Latreille M; Homery MC; Babin V; Benamor S; Pichon S; Guinet-Morlot F; Minutello AM
    Clin Infect Dis; 2024 Jun; 78(6):1748-1756. PubMed ID: 38478634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study.
    Gogtay NJ; Munshi R; Ashwath Narayana DH; Mahendra BJ; Kshirsagar V; Gunale B; Moore S; Cheslock P; Thaker S; Deshpande S; Karande S; Kumbhar D; Ravish HS; Harish BR; Pisal SS; Dhere R; Parulekar V; Blackwelder WC; Molrine DC; Kulkarni PS
    Clin Infect Dis; 2018 Jan; 66(3):387-395. PubMed ID: 29020321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2/3 trial.
    Matson MA; Schenker E; Stein M; Zamfirova V; Nguyen HB; Bergman GE
    Hum Vaccin Immunother; 2020; 16(2):452-459. PubMed ID: 31549899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous human rabies immunoglobulin for post-exposure prophylaxis: serum rabies neutralizing antibody concentrations and side-effects.
    Aoki FY; Rubin ME; Friesen AD; Bowman JM; Saunders JR
    J Biol Stand; 1989 Jan; 17(1):91-104. PubMed ID: 2646301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rabies neutralizing antibody in serum of children compared to adults following post-exposure prophylaxis.
    Aoki FY; Rubin ME; Fast MV
    Biologicals; 1992 Dec; 20(4):283-7. PubMed ID: 1305405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults.
    Gogtay N; Thatte U; Kshirsagar N; Leav B; Molrine D; Cheslock P; Kapre SV; Kulkarni PS;
    Vaccine; 2012 Nov; 30(50):7315-20. PubMed ID: 23010601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.
    Kerdpanich P; Chanthavanich P; De Los Reyes MR; Lim J; Yu D; Ama MC; Mojares Z; Casula D; Arora AK; Pellegrini M
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006340. PubMed ID: 29874228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices.
    Manning SE; Rupprecht CE; Fishbein D; Hanlon CA; Lumlertdacha B; Guerra M; Meltzer MI; Dhankhar P; Vaidya SA; Jenkins SR; Sun B; Hull HF;
    MMWR Recomm Rep; 2008 May; 57(RR-3):1-28. PubMed ID: 18496505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rabies postexposure prophylaxis in routine practice in view of the new Centers for Disease Control and Prevention and World Health Organization recommendations.
    Uwanyiligira M; Landry P; Genton B; de Valliere S
    Clin Infect Dis; 2012 Jul; 55(2):201-5. PubMed ID: 22550115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Theater Medical Data Store and Reportable Medical Event Records to Theater Animal Bite Reports Submissions, 2018-2019.
    Knobbe MG; Aden BJ; Ashbaugh HR
    Mil Med; 2024 May; 189(5-6):e1166-e1173. PubMed ID: 37997678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bat Bites and Rabies PEP in the Croatian Reference Centre for Rabies 1995-2020.
    Vodopija R; Lojkić I; Hamidović D; Boneta J; Primorac D
    Viruses; 2024 May; 16(6):. PubMed ID: 38932168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world evidence of rabies post-exposure prophylaxis in Serbia: Nation-wide observational study (2017-2019).
    Banović P; Mijatović D; Simin V; Vranješ N; Meletis E; Kostoulas P; Obregon D; Cabezas-Cruz A
    Travel Med Infect Dis; 2024; 58():102697. PubMed ID: 38369074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Corticosteroids on RVNA production of a patient with acute disseminated encephalomyelitis following rabies vaccination as well as administration of HRIG.
    Peng J; Chen L; Zhu ZG; Zhu ZR; Hu Q; Fang Y
    Hum Vaccin Immunother; 2014; 10(12):3622-6. PubMed ID: 25668669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody responses to human diploid cell vaccine for rabies with and without human rabies immune globulin.
    Mertz GJ; Nelson KE; Vithayasai V; Makornkawkeyoon S; Rosanoff EI; Tint H; Wiktor TJ
    J Infect Dis; 1982 May; 145(5):720-7. PubMed ID: 7077095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models.
    Zhai LL; Wang H; Zhao W; Zhang SF; Miao FM; Cao Y; Chen C; Li YF; Gao J; Lv RY; Zhang SX; Cao JB; Zhang XF; Yang MM; Zhang B; Zhao J; Wei JS; Gao J
    Travel Med Infect Dis; 2022; 46():102267. PubMed ID: 35091118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG).
    Kansagra K; Parmar D; Mendiratta SK; Patel J; Joshi S; Sharma N; Parihar A; Bhoge S; Patel H; Kalita P; Munshi R; Kurmi P; Shah R; Gupta A; Bhalla H; Bekkalele H; Verma R; Agarwal D; Sharma S; Gawande A; Chhaya G
    Clin Infect Dis; 2021 Nov; 73(9):e2722-e2728. PubMed ID: 32556113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 1-week intradermal dose-sparing regimen for rabies post-exposure prophylaxis (RESIST-2): an observational cohort study.
    Cantaert T; Borand L; Kergoat L; Leng C; Ung S; In S; Peng Y; Phoeun C; Hing C; Taing CN; Saman M; Ong S; Mey C; Choeung R; Ly S; Dussart P; Bourhy H; Tarantola A
    Lancet Infect Dis; 2019 Dec; 19(12):1355-1362. PubMed ID: 31570311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.